Epilepsy and Alzheimer’s: nasal spray should protect against seizures
An American research team developed a novel peptide that supports the natural mechanism with which the brain seizures prevented, which are based on an overreaction of neurons. Such seizures are particularly common in Alzheimer’s or epilepsy instead of. The peptide can have a nasal spray be administered.
researchers of Medical College of Georgia an der Augusta University (US) are hiring peptide administrable by nasal spray suggest that susceptibility to uncontrolled electrical activity in the brain can be curbed, and so on Seizures in Alzheimer’s and epilepsy could protect. The research results were recently published in the journal “JCI Insight” presented.
New peptide soothes the brain
The peptide labeled A1R-CT According to the study, it is able out of control neuron activity in the brain to soothe. Such excessive reactions are particularly common after traumatic brain injuries and strokes. Over 60 percent of all Alzheimer’s sufferers suffer from such seizures.
Since the peptide can be administered quickly and easily through the nose, it could also prove to be a new drug for the treatment of acute seizures suit.
How does the peptide A1R-CT work?
As the working group explains, the peptide inhibits a protein called Neurabin. This occurs mainly in the brain and is actually responsible for the overactivity of the so-called adenosine-1 receptor to prevent.
What does the adenosine 1 receptor do?
“This is a powerful receptor that silences the neurons”explained Professorin Dr. Qin Wang from the research team. If the A1 receptor is activated too much, we fall asleep, says the lead scientist. According to her, caffeine, for example, is a substance that blocks the A1 receptor and thus prevents you from falling asleep.
“The neurons try to make sure everything stays under control, and for most of us that works pretty well.”explained Dr. Money further. That way we don’t just fall asleep at a desk, for example, or have uncontrolled seizures.
In Alzheimer’s, communication in the brain is disrupted
In the brain of Alzheimer-Affected, however, the communication of the neurons is affected by the characteristic accumulation of amyloid and tau proteins disturbed. This can lead to stress reactions in the brain, causing neurons to become overly excited.
The researchers therefore consider the A1 receptor, which has molecules that are widespread in the body Adenosine is activated, for a promising treatment target Calming down neuron overactivity.
The A1 receptor is widespread in the body
The only problem is that A1 is distributed throughout the body, including the heart, lungs and kidneys. A drug that targets the A1 receptor directly would therefore likely result in extensive side effects throughout the body.
Neurabin controls the A1 receptor in the brain
As Wang’s working group found out, the protein neurabin, which is used for the targeted control of the A1 receptor in the brain, also appears to be mainly found in the brain. So the team developed a peptide that Neurabin inhibitsrather than interacting directly with the A1 receptor.
“The fact that neurabin is primarily found in the brain means that changing its activity should not have the potential effects throughout the body that a direct change in A1 receptor activity would have.”approved Wang.
Hyperpolarization of the neurons
By inhibiting neurabin, the A1 receptors in the brain are activated more. As a result, the excitation state of neurons is dampened. The researchers refer to this mechanism as hyperpolarization. This means that neurons are less likely to emit an electrical signal.
Peptide A1R-CT could prevent severe seizures
In the mouse model, the working group has already demonstrated that the peptide A1R-CT by inhibiting neurabin severe epileptic seizures as well as typical seizures that occur as part of Alzheimer’s disease, can prevent.
The tests on mice also showed that the peptide had a similar effect when administered via a nasal spray as when injected directly into the brain. This greatly increases the potential clinical benefit of the peptide.
The peptide is now to be tested on humans
The next step is to test the peptide on humans. For this purpose, it must first be determined for the individual clinical pictures in which the clinical use of the agent is possible, which dose must be administered and at what times in order to achieve the optimal result. (vb)
Author and source information
This text corresponds to the specifications of medical specialist literature, medical guidelines and current studies and has been checked by medical professionals.
Graduate editor (FH) Volker Blasek
- Medical College of Georgia: Peptide delivered by nasal spray can reduce seizure activity, protect neurons in Alzheimer’s, epilepsy (veröffentlicht: 16.08.2022), eurekalert.org
- Shalini Saggu, Yunjia Chen, Qin Wang, et al.: A peptide blocking the ADORA1-neurabin interaction is anticonvulsant and inhibits epilepsy in an Alzheimer’s model; in: JCI Insight (2022), ncbi.nlm.nih.gov
This article contains general advice only and should not be used for self-diagnosis or treatment. He can not substitute a visit at the doctor.